Sorrento Announces Phase II Results Of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress Of The European Society For Medical Oncology
IMC-001, a PD-L1 monoclonal antibody selected from Sorrento's G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response
‘Aeroclean Technologies Has Received FDA 510(K) Clearance On 11/30/2022 For Its Purgo UV Air Purifier’ – FDA
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223328
Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce U.S. FDA Acceptance Of A Resubmitted Biologics License Application For Pegunigalsidase Alfa For The Proposed Treatment Of Fabry Disease
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
HilleVax Announces Immunogenicity Results For Run-In Cohort Of NEST-IN1 Phase 2b Clinical Trial Of HIL-214 Norovirus Vaccine Candidate
HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified immunogenicity analysis of the 203 subjects
Immuron Submits IND Application To FDA For Travelan
Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)
Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA
Clinical Trial to examine a
Health And Human Services Issues Statement On Mpox; Says Does Not Expect That It Needs To Renew The Emergency Declaration When It Ends On January 31, 2023
https://www.hhs.gov/about/news/2022/12/02/statement-from-hhs-secretary-becerra-on-mpox.html
UroGen Announces New Data from the OPTIMA II Study; Co Says Data Show Median Durability Of Response Of 24.4 Months For UGN-102, An Investigational Non-Surgical Chemoablative Treatment For Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
-- Results from this ongoing, noninterventional rollover study were presented at the 23rd Annual Society of Urological Oncology (SUO) Meeting in San Diego